Impact of vulnerability on concurrent chemoradiotherapy outcomes in patients with locally advanced non-small cell lung cancer using an integrated clinical trial database.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
1288 patients with locally advanced NSCLC treated with CCRT.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Clinical vulnerability was associated with poorer OS after CCRT, mediated by multiple factors, including reduced CDDP use, lower subsequent therapy rates, and cachexia. Individualized strategies that balance treatment intensity, supportive care, and access to post-CCRT are essential for improving outcomes.
[BACKGROUND] The effect of vulnerability on the outcomes of patients with locally advanced non-small cell lung cancer (NSCLC) undergoing concurrent chemoradiotherapy (CCRT) remains unclear.
APA
Morimoto K, Yamada T, et al. (2026). Impact of vulnerability on concurrent chemoradiotherapy outcomes in patients with locally advanced non-small cell lung cancer using an integrated clinical trial database.. Therapeutic advances in medical oncology, 18, 17588359251414535. https://doi.org/10.1177/17588359251414535
MLA
Morimoto K, et al.. "Impact of vulnerability on concurrent chemoradiotherapy outcomes in patients with locally advanced non-small cell lung cancer using an integrated clinical trial database.." Therapeutic advances in medical oncology, vol. 18, 2026, pp. 17588359251414535.
PMID
41555860 ↗
Abstract 한글 요약
[BACKGROUND] The effect of vulnerability on the outcomes of patients with locally advanced non-small cell lung cancer (NSCLC) undergoing concurrent chemoradiotherapy (CCRT) remains unclear.
[OBJECTIVES] To examine the impact of vulnerability on the outcomes in patients with locally advanced NSCLC undergoing CCRT.
[DESIGN] We analyzed data from the Japan Lung Cancer Society Integrated Clinical Trial Database, which included 1288 patients with locally advanced NSCLC treated with CCRT.
[METHODS] Vulnerability was defined as meeting one or more of the following: age ⩾75 years; history of chronic obstructive pulmonary disease (COPD) or emphysema; chronic kidney disease with at least one other comorbidity; or cancer cachexia (C-reactive protein >1.0 mg/dL and albumin <3.5 g/dL).
[RESULTS] Among 741 eligible patients, 283 (38.2%) were classified as vulnerable. Vulnerable patients had significantly shorter overall survival (OS; 19.7 vs 27.4 months, = 0.003), whereas progression-free survival (PFS) did not differ significantly (8.8 vs 10.4 months, = 0.151). In multivariate analysis adjusted for factors including cisplatin (CDDP) use, the association between vulnerability and OS was attenuated (hazard ratio = 1.221, 95% confidence interval: 0.959-1.555, = 0.105). The vulnerable patients were significantly less likely to undergo subsequent therapies (60.4% vs 71.6%, = 0.003). Among the vulnerability components, cachexia showed the strongest association with shorter PFS (8.0 vs 10.5 months, = 0.009) and OS (16.5 vs 27.4 months, < 0.001).
[CONCLUSION] Clinical vulnerability was associated with poorer OS after CCRT, mediated by multiple factors, including reduced CDDP use, lower subsequent therapy rates, and cachexia. Individualized strategies that balance treatment intensity, supportive care, and access to post-CCRT are essential for improving outcomes.
[OBJECTIVES] To examine the impact of vulnerability on the outcomes in patients with locally advanced NSCLC undergoing CCRT.
[DESIGN] We analyzed data from the Japan Lung Cancer Society Integrated Clinical Trial Database, which included 1288 patients with locally advanced NSCLC treated with CCRT.
[METHODS] Vulnerability was defined as meeting one or more of the following: age ⩾75 years; history of chronic obstructive pulmonary disease (COPD) or emphysema; chronic kidney disease with at least one other comorbidity; or cancer cachexia (C-reactive protein >1.0 mg/dL and albumin <3.5 g/dL).
[RESULTS] Among 741 eligible patients, 283 (38.2%) were classified as vulnerable. Vulnerable patients had significantly shorter overall survival (OS; 19.7 vs 27.4 months, = 0.003), whereas progression-free survival (PFS) did not differ significantly (8.8 vs 10.4 months, = 0.151). In multivariate analysis adjusted for factors including cisplatin (CDDP) use, the association between vulnerability and OS was attenuated (hazard ratio = 1.221, 95% confidence interval: 0.959-1.555, = 0.105). The vulnerable patients were significantly less likely to undergo subsequent therapies (60.4% vs 71.6%, = 0.003). Among the vulnerability components, cachexia showed the strongest association with shorter PFS (8.0 vs 10.5 months, = 0.009) and OS (16.5 vs 27.4 months, < 0.001).
[CONCLUSION] Clinical vulnerability was associated with poorer OS after CCRT, mediated by multiple factors, including reduced CDDP use, lower subsequent therapy rates, and cachexia. Individualized strategies that balance treatment intensity, supportive care, and access to post-CCRT are essential for improving outcomes.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Association of preoperative frailty and prognostic nutritional index with postoperative delirium in elderly gastric cancer patients: A single-center observational study.
- Combined Impact of Neoadjuvant Therapy and Preoperative Cachexia in Patients Undergoing Pancreatoduodenectomy: Is There a "Double Jeopardy"? A National Cohort Study Investigating the Association with Short- and Long-Term Outcomes.
- Complete Response to Chemo-Immunotherapy in Recurrent Unresectable Tracheal Squamous Cell Carcinoma: A Case Report.
- Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysis.
- Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents.
- Nutritional pathways from treatment to management of sarcopenia in patients with gastric cancer: a narrative review.